Ruby Siegel

Dr. Ruby Siegel

Washington State University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
FVFlavio Vincenti
Flavio Vincenti
OBOriol Bestard
Oriol Bestard
ABAmarpali Brar
Amarpali Brar
JCJosep M. Cruzado
Josep M. Cruzado
DSDaniel Serón
Daniel Serón
MSMark Stegall
Mark Stegall
Significance Statement: There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity. The short treatment period and long follow-up of this study allowed for the understanding of the mechanism and timing for any antibody rebound. Isatuximab could be further investigated as an option for adjunct therapy to existing desensitization for patients on the kidney transplant waitlist. Background: Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase the chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. Methods: This was an open-label single-arm phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, cohorts A and B, which enrolled cPRA ≥99.90% and 80.00% to <99.90%, respectively. Results: Twenty-three patients (12 cohort A, 11 cohort B) received isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks. Isatuximab was well tolerated with pharmacokinetic and pharmacodynamic profiles that indicated similar exposure to multiple myeloma trials. It resulted in decreases in CD38+ plasmablasts, plasma cells, and NK cells and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, on the basis of a predefined composite desensitization end point, was 83.3% and 81.8% in cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall, cPRA values were minimally affected, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cutoff (median follow-up of 68 weeks), six patients received transplant offers, of which four were accepted. Conclusions: In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity. Clinical Trial registration number: NCT04294459.

6 September 2019 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
Ruby SiegelRuby Siegel
Ruby Siegel
SBS. Louis Bridges
S. Louis Bridges
SASalahuddin Ahmed
Salahuddin Ahmed
Human leukocyte antigen c (HLA‐C) is a polymorphic membrane protein encoded by the HLA‐C gene in the class I major histocompatibility complex. HLA‐C plays an essential role in protection against cancer and viruses but has also been implicated in allograft rejection, preeclampsia, and autoimmune disease. This review summarizes reports and proposed mechanisms for the accessory role of HLA‐C in rheumatic diseases. Historically, contributions of HLA‐C to rheumatic diseases were eclipsed by the stronger association with HLA‐DRB1 alleles containing the “shared epitope” with rheumatoid arthritis. Larger genetic association studies and more powerful analytical approaches have revealed independent associations of HLA‐C with rheumatic disease–associated phenotypes, including development of anticitrullinated peptide antibodies. HLA‐C functions by presenting antigens to T cells and by binding activatory and inhibitory receptors on natural killer (NK) cells, but the exact mechanisms by which the HLA‐C locus contributes to autoimmunity are largely undefined. Studies have suggested that HLA‐C and NK cell receptor polymorphisms may predict responsiveness to pharmacotherapy. Understanding the mechanisms of the role of HLA‐C in rheumatic disease could uncover therapeutic targets or guide precision pharmacologic treatments.

Verified
Journal Article
Open access
PDF file
PPPaul M Panipinto
Paul M Panipinto
ASAnil Singh
Anil Singh
FSFarheen S. Shaikh
Farheen S. Shaikh
Ruby SiegelRuby Siegel
Ruby Siegel
MCMukesh Chourasia
Mukesh Chourasia
SASalahuddin Ahmed
Salahuddin Ahmed
TGF β-activated kinase 1 (TAK1) is an important participant in inflammatory pathogenesis for diseases such as rheumatoid arthritis (RA) and gouty arthritis. The central position it occupies between the mitogen activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) pathways makes it an attractive therapeutic target. As this field has developed in recent years, several novel inhibitors have been presented as having specific activity that reduces the TAK1 function either covalently as in the case of 5Z-7-oxozeanol (5Z7O) or reversibly (NG-25). However, the mechanism through which takinib elicits its anti-inflammatory activity remains elusive. While this inhibitor shows great promise, a thorough analysis of its inhibitor function and its potential off-target effects is necessary before addressing its clinical potential or its use in inflammatory conditions. An analysis through Western blot showed an unexpected increase in IL-1β-induced TAK1 phosphorylation—a prerequisite for and indicator of its functional potential—by takinib while simultaneously demonstrating the inhibition of the JAK/STAT pathway in human rheumatoid arthritis synovial fibroblasts (RASFs) in vitro. In THP-1 monocyte-derived macrophages, takinib again led to the lipopolysaccharide-induced phosphorylation of TAK1 without a marked inhibition of the TAK1 downstream effectors, namely, of c-Jun N-terminal kinase (JNK), phospho-c-Jun, NF-κB phospho-p65 or phospho-IκBα. Taken together, these findings indicate that takinib inhibits inflammation in these cells by targeting multiple signaling pathways, most notably the JAK/STAT pathway in human RASFs.

4 August 2026 in HLA
Verified
Journal Article
Closed access
Ruby SiegelRuby Siegel
Ruby Siegel
KHKatrin Hacke
Katrin Hacke
CGCatherine L. Gebhart
Catherine L. Gebhart
BFBrian J. Franz
Brian J. Franz
AJAndrés Jaramillo
Andrés Jaramillo

21 May 2026 in HLA
Verified
Journal Article
Closed access
PDF file
Ruby SiegelRuby Siegel
Ruby Siegel
KHKatrin Hacke
Katrin Hacke
CGCatherine L. Gebhart
Catherine L. Gebhart
RRRose M. Ridgley
Rose M. Ridgley
AJAndrés Jaramillo
Andrés Jaramillo

20 February 2026 in HLA
Verified
Journal Article
Closed access
Ruby SiegelRuby Siegel
Ruby Siegel
KHKatrin Hacke
Katrin Hacke
RRRose M. Ridgley
Rose M. Ridgley
DTDanielle M. Troop
Danielle M. Troop
AJAndrés Jaramillo
Andrés Jaramillo